Stock Analysis
- United States
- /
- Biotech
- /
- NasdaqGS:IGMS
IGM Biosciences Second Quarter 2024 Earnings: Misses Expectations
IGM Biosciences (NASDAQ:IGMS) Second Quarter 2024 Results
Key Financial Results
- Net loss: US$47.9m (loss narrowed by 26% from 2Q 2023).
- US$0.79 loss per share (improved from US$1.43 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
IGM Biosciences Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 98%. Earnings per share (EPS) was also behind analyst expectations.
Looking ahead, revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 2.3% from a week ago.
Risk Analysis
It is worth noting though that we have found 4 warning signs for IGM Biosciences (1 is concerning!) that you need to take into consideration.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:IGMS
IGM Biosciences
A clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases.